Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma
PLOS ONE · 22.01.2025 · 20 (1) · e0317401
DOI: 10.1371/journal.pone.0317401 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 22.01.2025. Verfasst von Lei Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America. Hauptthemen laut MEDLINE: Glypicans, Carcinoma, Hepatocellular, Liver Neoplasms, Killer Cells, Natural. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer and the second leading cause of cancer-related mortality globally. Despite advancements in current HCC treatment, it remains a malignancy with poor prognosis. Therefore, developing novel treatment options for patients with HCC is urgently needed. Chimeric antigen receptor (CAR)-modified natural killer (NK) cells have demonstrated potent anti-tumor effects, making them as a promising immunotherapy strategy for cancer treatment. Glypican-3 (GPC3), a cell surface oncofetal glycoprotein, is highly expressed in most HCC tissues, but not in normal tissues, and functions as a key driver of carcinogenesis. Given its high expression level on the cell surface, GPC3 is considered as an attractive immunotherapy target for HCC. In this study, two GPC3-specific CAR-NK cells, NK92MI/HN3 and NK92MI/HS20, were established using NK92MI cells, a modified IL-2-independent NK cell line. These cell lines were engineered with third generation GPC3-specific CARs, and their activities were subsequently evaluated in the treatment of HCC. We found that NK92MI/HN3 cells, rather than NK92MI/HS20 cells, exhibited a significant cytotoxicity effect against GPC3 + HepG2 cells in vitro and efficiently suppressed tumor growth in a xenograft model using NSG mice. In addition, irradiated NK92MI/HN3 cells displayed similar anti-tumor efficacy to unirradiated NK92MI/HN3 cells. Furthermore, we observed that NK92MI/HN3 cells showed higher killing activity against the GPC3 isoform 2 overexpression cell line (Sk-Hep1-v2) than those with GPC3 isoform 1 overexpression cell line (Sk-Hep1-v1). This suggest that the presence of different GPC3 isoforms in HCC may impact the cytotoxicity activity of NK92MI/HN3 cells and potentially influence therapeutic outcomes. These findings highlight the effective anti-HCC effects of NK92MI/HN3 cells and reveal the role of GPC3 isoforms in influencing therapy outcomes, suggesting that isoform analysis should be considered to optimize CAR-NK therapies to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America.
- Department of Pathology and Laboratory Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America.
ORCID-Profile: Dongfang Liu, Chen Liu
Förderung
- NCATS NIH HHS
Zitieren
APA
Yang, L., Pham, K., Xi, Y., Wu, Q., Liu, D., Robertson, K. D., & Liu, C. (2025). Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PLOS ONE, 20(1), e0317401. https://doi.org/10.1371/journal.pone.0317401
Vancouver
Yang L, Pham K, Xi Y, Wu Q, Liu D, Robertson KD, et al. Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PLOS ONE. 2025;20(1):e0317401. doi:10.1371/journal.pone.0317401
BibTeX
@article{Yang2025,
author = {Yang, Lei and Pham, Kien and Xi, Yibo and Wu, Qunfeng and Liu, Dongfang and Robertson, Keith D and Liu, Chen},
title = {Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {1},
pages = {e0317401},
doi = {10.1371/journal.pone.0317401}
}
EUVIMED